share_log

CervoMed Shares Are Trading Higher After the Company Announced Its Orval Investigational Drug Neflamapimod Was Granted Orphan Drug Designation Status by the FDA for the Treatment of Frontotemporal Dementia.

Benzinga ·  Nov 27, 2024 23:14
CervoMed Shares Are Trading Higher After the Company Announced Its Orval Investigational Drug Neflamapimod Was Granted Orphan Drug Designation Status by the FDA for the Treatment of Frontotemporal Dementia.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment